bladder cancer

ASCO20 Virtual Scientific Program: #ASCO20
May 28, 2020
Brielle Gregory, ASCO staff

Programa científico virtual de ASCO20: Inmunoterapia para el cáncer colorrectal metastásico, terapia de mantenimiento para el cáncer de vejiga, medicina de precisión para el cáncer infantil, inmunoterapia para la ETG y terapia dirigida para el NSCLC

Spanish
Brielle.Gregory

Lea los puntos destacados de la investigación del programa científico virtual ASCO20 que se acaban de publicar. Incluyen estudios sobre inmunoterapia para el cáncer colorrectal metastásico y la enfermedad trofoblástica gestacional, terapia de mantenimiento para el cáncer de vejiga avanzado, el potencial de la medicina de precisión para el cáncer infantil y la terapia dirigida después de la cirugía por EGFR (receptor del factor de crecimiento epidérmico), positivo de cáncer de pulmón de células no pequeñas.

Read More >>
ASCO20 Virtual Scientific Program: #ASCO20
May 28, 2020
Brielle Gregory, ASCO staff

ASCO20 Virtual Scientific Program: Immunotherapy for Colorectal Cancer, Maintenance Therapy for Bladder Cancer, Precision Medicine in Childhood Cancers, Treatment for Gestational Trophoblastic Disease, and Targeted Therapy for Non-Small Cell Lung Cancer

English
Brielle.Gregory

Read research highlights just released from the ASCO20 Virtual Scientific Program. They include studies on immunotherapy for metastatic colorectal cancer and gestational trophoblastic disease, maintenance therapy for advanced bladder cancer, the potential of precision medicine for childhood cancers, and targeted therapy after surgery for EGFR-positive non-small cell lung cancer.

Read More >>
2019 ASCO ® Annual Meeting; #ASCO19
June 3, 2019
Greg Guthrie, ASCO staff

ASCO Annual Meeting 2019: Laparoscopic Surgery for Metastatic Colorectal Cancer, Expanding Eligibility Criteria for Advanced Non-Small Cell Lung Cancer, and a New Targeted Therapy for Advanced Bladder Cancer

English
gregguthrie

The ASCO Annual Meeting is where many new cancer research findings are announced. Today’s key research highlights include minimally invasive surgery for liver metastases in colorectal cancer, expanding clinical trial eligibility criteria for non-small cell lung cancer, and a new targeted therapy for advanced bladder cancer.

Read More >>
2017 Clinical Cancer Advances
February 1, 2017
Greg Guthrie, ASCO staff

Immunotherapy 2.0: The 2017 Clinical Cancer Advance of the Year

English
gregguthrie

The 2017 Clinical Cancer Advances report of the American Society of Clinical Oncology has announced that the Advance of the Year is Immunotherapy 2.0. Why 2.0? Because the role of immunotherapy in cancer care is expanding, and oncologists are learning how to use it more effectively.

Read More >>

Pages

Subscribe to RSS - bladder cancer